Pharma Company Restructuring Cost - history!
The company was founded in through the merger of the Swedish Astra AB and the British Zeneca Group [7] [8] itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology in , MedImmune in , Spirogen in and Definiens by MedImmune in It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg , Sweden and Gaithersburg in Maryland , U. In , its drug Iressa was approved in Japan as monotherapy for non-small cell lung cancer. In , AstraZeneca acquired Novexel Corp, an antibiotics discovery company formed in as a spin-off of the Sanofi-Aventis anti-infectives division. In February , AstraZeneca and Amgen announced a collaboration on treatments for inflammatory diseases. Pharma Company Restructuring CostPharma Company Restructuring Cost Video
How Drug Prices Work - WSJNASDAQ: IMNP "Immune" or the "Company"a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced a major corporate restructuring with the objective of prioritizing and segregating its research and development efforts on a focused set of products in inflammatory disease and dermatology and strengthening its financial position.
Navigation menu
Under the leadership of Dr. Teper, Source will aim to grow into a global specialty biopharmaceutical company through these product candidates and the acquisition of additional late stage or commercial stage oncology products. A potential spin-off of Cytovia into a stand-alone company pursuing an independent path from Immune Restructjring provide several advantages:.
The potential Cytovia spin-off will establish each division as a separate company with a focused strategy and will enable each company to enhance its business focus, better align its resources to achieve strategic priorities, target investors attracted to its unique business profile, and ultimately unlock significant value for both companies", said Dr Daniel Teper. In connection with this restructuring, the Company's Board has accepted the resignation of Dr. Daniel Teper as CEO of Immune, effective immediately, so that he may focus his Pharma Company Restructuring Cost exclusively on Puarma Cytovia. The terms of the resignation are specified in a Separation Agreement entered into by Pharma Company Restructuring Cost between Dr. Teper and the Company on April 21, Teper will remain a member of the Company's Board and will focus his efforts, in conjunction Compwny the Board, on developing and beginning execution of the plan to spin off Cytovia into an independent, stand-alone oncology business.
USEFUL LINKS
Maza served as a consultant to the Company from November to January In Cist with his appointment to the position of interim CEO, Mr. Maza will resign from the Pharma Company Restructuring Cost Committee of the Board but will continue to Pharma Company Restructuring Cost as a director.
Monica E. Under the leadership of Mr. Maza and Dr. Luchi, Immune will focus its business on immuno-inflammation in general, and immuno-dermatology in particular, by developing its core asset, bertilimumab, a first in class human monoclonal antibody in phase 2 development in bullous pemphigoid and ulcerative colitis and with application for severe atopic dermatitis. Immune intends to continue to focus on the development of topical nano-cyclosporine for the treatment of atopic dermatitis and moderate psoriasis.
About Immune Pharmaceuticals Inc. Immune Pharmaceuticals Inc. NASDAQ: IMNP applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in Phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include eRstructuring dermatitis, Crohn's disease, severe asthma and Non-Alcoholic Steato-Hepatitis NASHan inflammatory liver disease.
Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis.
TRADING DOCUMENTATION
Maxim Pharmaceuticals Inc. For more information, visit Immune's website at www. Forward-Looking Statements This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of You are urged to Cosh statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," Phatma "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be Pharma Company Restructuring Cost and forward-looking.
Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. Forward-looking statements also include, among others, statements regarding the Board's corporate restructuring strategy, and the Company's ability to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that either party will ever successfully complete the anticipated corporate restructuring, or that Pharma Company Restructuring Cost Company will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value source shareholders.
These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, Q and K and other filings with the U. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, Pharma Company Restructuring Cost are available at www. You are cautioned not Cots place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.]
I can not participate now in discussion - it is very occupied. But I will be released - I will necessarily write that I think on this question.